Cancer Genetics Inc (CGIX) Trading Down 0.5%
Shares of Cancer Genetics Inc (NASDAQ:CGIX) fell 0.5% during mid-day trading on Monday . The company traded as low as $2.09 and last traded at $2.16, with a volume of 86,262 shares changing hands. The stock had previously closed at $2.17.
Separately, Zacks Investment Research downgraded Cancer Genetics from a “buy” rating to a “hold” rating in a research report on Monday, May 16th.
The firm has a 50-day moving average price of $2.06 and a 200 day moving average price of $2.32. The firm’s market cap is $32.90 million.
Cancer Genetics (NASDAQ:CGIX) last posted its quarterly earnings data on Wednesday, August 10th. The company reported ($0.28) EPS for the quarter, topping analysts’ consensus estimates of ($0.33) by $0.05. During the same quarter in the prior year, the business posted ($0.51) EPS. The company had revenue of $7 million for the quarter, compared to analysts’ expectations of $6.50 million. The company’s revenue for the quarter was up 67.3% compared to the same quarter last year. On average, analysts forecast that Cancer Genetics Inc will post ($1.19) EPS for the current year.
In related news, Director John Pappajohn acquired 147,500 shares of the company’s stock in a transaction that occurred on Monday, August 15th. The stock was purchased at an average price of $2.16 per share, for a total transaction of $318,600.00. Following the transaction, the director now owns 2,162,387 shares in the company, valued at approximately $4,670,755.92. The purchase was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through this link.
Cancer Genetics, Inc is engaged in the field of personalized medicine, enabling precision medicine in the field of oncology through its diagnostic products and services, and molecular markers. The Company develops, commercializes and provides molecular- and biomarker-based tests and services that enable physicians to personalize the clinical management of each individual patient by providing genomic information to diagnose, monitor and inform cancer treatment, and enable biopharmaceutical companies engaged in oncology trials to select candidate populations and manage adverse drug reactions by providing information regarding genomic factors influencing subject responses to therapeutics.
Get Analysts' Upgrades and Downgrades Daily - Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.